Scientists Develop Molecule to Treat Inflammatory Diseases

Advertisement
By Press Trust of India | Updated: 17 February 2015 17:20 IST

Scientists in Australia have developed a marvel molecule that fights one of the main causes of inflammatory diseases and could be the key to improved treatments for diseases like Alzheimer's, arthritis and multiple sclerosis.

Researchers at University of Queensland, in collaboration with an international team, worked to develop the molecule that could lead to safer, cheaper treatments.

Advertisement

The molecule known as MCC950 could help prevent inflammation in immune cells, Matt Cooper of the University's Institute for Molecular Bioscience was quoted as saying by the ABC.

"It is one of the first molecules we've ever seen that can attack this complex we call the inflammasome - and that's in every one of our immune cells, it's a key part of our response to infection," he said.

Advertisement

"But when it goes wrong, it activates these cells so then people become chronically agitated and [their] immune system goes into overdrive," he said.

Stating that the molecule was tested on animals and blood samples from patients in the US, Cooper said, "Patients have donated blood samples, these are patients with a very severe form of inflammation called Muckle-Wells syndrome".

Advertisement

(Also See: Genetic Links Found to Size of Brain Structures: Study)

"We can see in those patients this immune response, this inflammasome is overactive and when we give the compound to those blood samples in a laboratory we can stop that process."

Advertisement

Informing that the new molecule could be taken orally and would be cheaper to produce than current protein-based treatments, Cooper said, the molecule is very small and passes from the gut into bloodstream very quickly.

"But it also means it can go places that proteins can't get... particularly in the brain, and with multiple sclerosis into the CNS - the central nervous system," he said.

It was not clear whether the molecule could cure inflammatory diseases or just treat the symptoms, he added.

The study is a global venture with scientists from the US, Trinity College in Dublin and Germany.

The next step is clinical trials.

The research was published in the journal Nature Medicine.

 

Get your daily dose of tech news, reviews, and insights, in under 80 characters on Gadgets 360 Turbo. Connect with fellow tech lovers on our Forum. Follow us on X, Facebook, WhatsApp, Threads and Google News for instant updates. Catch all the action on our YouTube channel.

Advertisement

Related Stories

Popular Mobile Brands
  1. Oppo Find X9 Ultra With 200-Megapixel Periscope Camera Launched Globally
  2. Google Puts Together A-Team to Build Better Coding Models Than Anthropic
  3. Vivo X300 FE Roundup: Expected Price in India, Specifications
  4. Apple's iOS 27 Update Might Drop Support for These iPhone Models
  5. WhatsApp Plus Subscription: What Is It, Pricing, Features and Benefits
  1. NASA Shuts Down Voyager 1 Instrument to Extend Mission Life in Deep Space
  2. Oppo Enco Clip 2 With Open-Ear Design, Up to 40 Hours Total Battery Life Launched Alongside Oppo Watch X3 Mini
  3. Vivo Y6t Launched With 6,500mAh Battery, Snapdragon 4 Gen 2 SoC: Price, Specifications
  4. OCBC Partners Lion Global Investors and DigiFT to Launch Tokenised Gold Fund With GOLDX Token
  5. Oppo Pad 5 Pro Launched With 13,380mAh Battery, Snapdragon 8 Elite Gen 5 SoC Alongside Oppo Pad Mini: Price, Features
  6. Redmi K90 Max Launched With Dimensity 9500 SoC, 8,550mAh Battery and Active Cooling Fan: Price, Specifications
  7. Oppo Find X9 Ultra Launched With Snapdragon 8 Elite Gen 5 SoC, 200-Megapixel Periscope Camera: Price, Specifications
  8. Oppo Find X9s Pro Launched With 200-Megapixel Cameras, 7,025mAh Battery: Price, Specifications
  9. OnePlus Ace 6 Ultra Geekbench Listing Reveals MediaTek Dimensity 9500 Chip, 16GB RAM
  10. Motorola Edge 70 Pro+ Leaked Renders Hint at Design, Five Colour Options
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2026. All rights reserved.